PRTA

Rating neutralAI MemoPost-earnings T+3

Prothena

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

BMS decision on PRX019 advancement • 2026-12-31

Base target: $10 / p=50% prob

Biggest risk

The thesis remains dependent on partner execution and clinical outcomes years away. Cash guidance declined to approximately $259 million midpoint after buybacks, PRX019 advancement is uncertain, and recent officer dispositions add a secondary caution signal [#SEC-FORM4-2026-07-30].

Invalidation

Break below $6 or thesis failure.

What would change my mind?

Prothena retains a large cash position and multiple partnered late-stage programs. PADOVA findings, ongoing Phase 3 trials, and potential milestone payments support long-term optionality [#SEC-8K-2026-08-06].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

$10

p=50%

Bull target

$18

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 results reset cash outlook
Partnered clinical execution
Prothena retains a large cash position and multiple partnered late-stage programs.

BearKey bullets

Cash guidance is lower than the prior midpoint after share repurchases, and continued development spending could pressure runway.
Clinical-trial failure, delay, or regulatory setbacks across partnered programs.
Dependence on Roche, Novo Nordisk, and Bristol Myers Squibb for development, milestone timing, and commercialization.

WatchKey bullets

BMS decision on PRX019 advancement

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $10 (p=50%)

Target spread vs base: +89% / -42%

Scenario probabilities

Bull Target: $18 (p=25%)Base Target: $10 (p=50%)Bear Target: $6 (p=25%)

Commentary

The post-earnings tone is mildly constructive because of the cash balance, PADOVA publication, and continued partnered-program milestones, but the lower year-end cash midpoint offsets part of that benefit. The packet does not provide a verified post-release percentage move, analyst target changes, estimate revisions, or consensus surprise; social coverage is absent. This remains a monitoring-oriented, event-driven view rather than a high-conviction bullish thesis.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 results reset cash outlook
Partnered clinical execution

Scenarios

Bull Target (Scenario probability)

$18 / p=25% prob

Base Target (Scenario probability)

$10 / p=50% prob

Bear Target (Scenario probability)

$6 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
BMS decision on PRX019 advancement
Bristol Myers Squibb may decide by year-end 2026 whether to advance PRX019. Advancement could generate a $55 million clinical milestone; a no-go or delay would remove that validation and cash catalyst [#SEC-8K-2026-08-06].
Prob 45.00% • Move 18.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Q2 results reset cash outlook
2026-08-06
Q2 results showed $289.1 million of quarter-end cash and restricted cash, while updated year-end cash guidance is approximately $259 million midpoint after incorporating repurchases through July 30. The release also highlighted PADOVA results and continued partnered-program progress, but no verified consensus surprise or analyst revision is available [#SEC-8K-2026-08-06].
Prob 100% • Move 5% • Priced-in 70%

Long-term Catalysts

Months to a year

Partnered clinical execution
2029-12-31
Roche’s approximately 900-participant PARAISO trial for prasinezumab and Novo Nordisk’s approximately 1,280-participant CLEOPATTRA trial for coramitug are expected to reach primary completion in 2029. BMS’s TargetTau-1 trial is expected to complete in the first half of 2027. These programs offer substantial optionality but carry high clinical and timing risk [#SEC-8K-2026-08-06].
Prob 35% • Move 30% • Priced-in 15%

Risks

Cash guidance is lower than the prior midpoint after share repurchases, and continued development spending could pressure runway.
Clinical-trial failure, delay, or regulatory setbacks across partnered programs.
Dependence on Roche, Novo Nordisk, and Bristol Myers Squibb for development, milestone timing, and commercialization.
Low analyst coverage, absent social coverage, and loose peers reduce confidence in near-term price discovery.
Multiple officers reported share dispositions on July 28, 2026 [#SEC-FORM4-2026-07-30].
PRX019 may not advance, eliminating the potential $55 million milestone [#SEC-8K-2026-08-06].

Peers

Symbol	Summary
BNTC	Same-sector, similar-market-cap biotech comparator; direct operating and pipeline comparability is not established.
CABA	Same-sector, similar-market-cap biotech comparator; useful for event-risk context but not a validated valuation peer.
PBYI	Same-sector, similar-market-cap comparator, but its commercial profile limits direct comparison with Prothena’s partnered clinical pipeline.
QTTB	Same-sector, similar-market-cap biotech comparator; the packet does not establish indication or pipeline overlap.
RZLT	Same-sector, similar-market-cap biotech comparator; useful for small-cap biotech volatility context rather than precise valuation.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

BNTC

Same-sector, similar-market-cap biotech comparator; direct operating and pipeline comparability is not established.

CABA

Same-sector, similar-market-cap biotech comparator; useful for event-risk context but not a validated valuation peer.

PBYI

Same-sector, similar-market-cap comparator, but its commercial profile limits direct comparison with Prothena’s partnered clinical pipeline.

QTTB

Same-sector, similar-market-cap biotech comparator; the packet does not establish indication or pipeline overlap.

RZLT

Same-sector, similar-market-cap biotech comparator; useful for small-cap biotech volatility context rather than precise valuation.